Mild cognitive impairment (MCI) is a heterogeneous condition. Idiopathic REM sleep behavior disorder (iRBD) can be associated with MCI (MCI-RBD).
Objective:
To investigate neuropsychological and brain metabolism features of patients with MCI-RBD by comparison with matched MCI-AD patients. To explore their predictive value toward conversion to a full-blown neurodegenerative disease.
Methods:
Seventeen MCI-RBD patients (73.6±6.5 years) were enrolled. Thirty-four patients with MCI-AD were matched for age (74.8±4.4 years), Mini-Mental State Exam score and education with a case-control criterion. All patients underwent a neuropsychological assessment and brain 18F-FDG-PET. Images were compared between groups to identify hypometabolic volumes of interest (MCI-RBD-VOI and MCI-AD-VOI). The dependency of whole-brain scaled metabolism levels in MCI-RBD-VOI and MCI-AD-VOI on neuropsychological test scores was explored with linear regression analyses in both groups, adjusting for age and education. Survival analysis was performed to investigate VOIs phenoconversion prediction power.
Results:
MCI-RBD group scored lower in executive functions and higher in verbal memory compared to MCI-AD group. Also, compared with MCI-AD, MCI-RBD group showed relative hypometabolism in a posterior brain area including cuneus, precuneus, and occipital regions while the inverse comparison revealed relative hypometabolism in the hippocampus/parahippocampal areas in MCI-AD group. MCI-RBD-VOI metabolism directly correlated with executive functions in MCI-RBD (p = 0.04). MCI-AD-VOI metabolism directly correlated with verbal memory in MCI-AD (p = 0.001). MCI-RBD-VOI metabolism predicted (p = 0.03) phenoconversion to an alpha-synucleinopathy. MCI-AD-VOI metabolism showed a trend (p = 0.07) in predicting phenoconversion to dementia.
Conclusion:
MCI-RBD and MCI-AD showed distinct neuropsychological and brain metabolism profiles, that may be helpful for both diagnosis and prognosis purposes.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
2.
Domoto-ReillyK, SapolskyD, DickersonBC (2014) Mild cognitive impairment (MCI) stage of the frontotemporal dementias: Early diagnosis and management. Perspect Gerontol19, 57–64.
3.
MariaE, De BoerJ, OrieVK, WilliamsT, BakerMR, De OliveiraHM, PolvikoskiT, SilsbyM, MenonP, Van Den BosM, HallidayGM, Van Den BergLH, VanL, BoschD, Van DammeP, KiernanMC, Van EsMA, VucicS (2021) TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry92, 86–95.
4.
McKeithIG, FermanTJ, ThomasAJ, BlancF, BoeveBF, FujishiroH, KantarciK, MuscioC, O’BrienJT, PostumaRB, AarslandD, BallardC, BonanniL, DonaghyP, EmreM, GalvinJE, GalaskoD, GoldmanJG, GompertsSN, HonigLS, IkedaM, LeverenzJB, LewisSJG, MarderKS, MasellisM, SalmonDP, TaylorJP, TsuangDW, WalkerZ, TiraboschiP (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology94, 743–755.
5.
MassaF, ArnaldiD, De CesariF, GirtlerN, BrugnoloA, GrazziniM, BaucknehtM, MeliR, MorbelliS, PardiniM, SambucetiG, De CarliF, TiraboschiP, NobiliF (2019) Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiol Aging76, 9–17.
6.
ConsoliA, PasiM, PantoniL (2012) Vascular mild cognitive impairment: Concept, definition, and directions for future studies. Aging Clin Exp Res24, 113–116.
7.
PetersenRC, LopezO, ArmstrongMJ, GetchiusTSD, GanguliM, GlossD, GronsethGS, MarsonD, PringsheimT, DayGS, SagerM, StevensJ, Rae-GrantA (2018) Practice guideline update summary: Mild cognitive impairment report of the guideline development, dissemination, and implementation. Neurology90, 126–135.
8.
ErkkinenMG, KimM-O, GeschwindMD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol10, a033118.
GagnonJF, VendetteM, PostumaRB, DesjardinsC, Massicotte-MarquezJ, PanissetM, MontplaisirJ (2009) Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson’s disease. Ann Neurol66, 39–47.
11.
ArnaldiD, ChincariniA, HuMT, SonkaK, BoeveB, MiyamotoT, PulighedduM, CockC De, TerzaghiM, PlazziG, TachibanaN, MorbelliS, Verbizier DeD, BossertI, AntelmiE, MeliR, BarberTR, BaucknehtM, BradleyKM, ZogalaD, McgowanDR (2021) Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain144, 278–287.
12.
NobiliF, ArbizuJ, BouwmanF, DrzezgaA, AgostaF, NestorP, WalkerZ, BoccardiM, FestariC, AltomareD, GandolfoF, OriniS, EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders (2018) European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol25, 1201–1217.
MelesSK, PaganiM, ArnaldiD, De CarliF, DessiB, MorbelliS, SambucetiG, JonssonC, LeendersKL, NobiliF (2017) The Alzheimer’s disease metabolic brain pattern in mild cognitive impairment. J Cereb Blood Flow Metab37, 3643–3648.
15.
ChetelatG, ArbizuJ, BarthelH, GaribottoV, LawI, MorbelliS, van de GiessenE, AgostaF, BarkhofF, BrooksDJ, CarrilloMC, DuboisB, FjellAM, FrisoniGB, HanssonO, HerholzK, HuttonBF, JackCR, LammertsmaAA, LandauSM, MinoshimaS, NobiliF, NordbergA, OssenkoppeleR, OyenWJG, PeraniD, RabinoviciGD, ScheltensP, VillemagneVL, ZetterbergH, DrzezgaA (2020) Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol19, 951–962.
16.
AASM (2014) International Classification of Sleep Disorders –Third Edition (ICSD-3). American Academy of Sleep Medicine, Darien, IL.
17.
LitvanI, GoldmanJG, TrösterAI, SchmandBA, WeintraubD, PetersenRC, MollenhauerB, AdlerCH, MarderK, Williams-GrayCH, AarslandD, KulisevskyJ, Rodriguez-OrozMC, BurnDJ, BarkerRA, EmreM (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord27, 349–356.
18.
MorbelliS, EspositoG, ArbizuJ, BarthelH, BoellaardR, BohnenNI, BrooksDJ, DarcourtJ, DicksonJC, DouglasD, DrzezgaA, DubroffJ, EkmekciogluO, GaribottoV, HerscovitchP, KuoP, LammertsmaA, PappataS, PeñuelasI, SeibylJ, SemahF, Tossici-BoltL, Van de GiessenE, Van LaereK, VarroneA, WannerM, ZubalG, LawI (2020) EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging47, 1885–1912.
19.
MattioliP, PardiniM, FamàF, GirtlerN, BrugnoloA, OrsoB, MeliR, FilippiL, GrisantiS, MassaF, BaucknehtM, MiceliA, TerzaghiM, MorbelliS, NobiliF, ArnaldiD (2021) Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. Eur J Nucl Med Mol Imaging48, 2834–2845.
20.
RinioloTC (1999) Using a large control group for statistical comparison: Evaluation of a between-groups median test. J Exp Educ68, 75–88.
21.
MolinuevoJL, BlennowK, DuboisB, EngelborghsS, LewczukP, Perret-LiaudetA, TeunissenCE, ParnettiL (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement10, 808–817.
22.
VarroneA, AsenbaumS, Vander BorghtT, BooijJ, NobiliF, NågrenK, DarcourtJ, KapucuÖL, TatschK, BartensteinP, Van LaereK (2009) EANM procedure guidelines for PET brain imagingusing [18 F]FDG, version 2. Eur J Nucl Med Mol Imaging36, 2103–2110.
23.
BottesiG, GhisiM, AltoèG, ConfortiE, MelliG, SicaC (2015) The Italian version of the Depression Anxiety Stress Scales-21: Factor structure and psychometric properties on community and clinical samples. Compr Psychiatry60, 170–181.
GilmanS, WenningGK, LowPA, BrooksDJ, MathiasCJ, TrojanowskiJQ, WoodNW, ColosimoC, DürrA, FowlerCJ, KaufmannH, KlockgetherT, LeesA, PoeweW, QuinnN, ReveszT, RobertsonD, SandroniP, SeppiK, VidailhetM (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology71, 670–676.
28.
FristonKJ, HolmesAP, WorsleyKJ, PolineJ-P, FrithCD, FrackowiakRSJ (1994) Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp2, 189–210.
29.
PortetF, OussetPJ, VisserPJ, FrisoniGB, NobiliF, ScheltensP, VellasB, TouchonJ (2006) Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease. J Neurol Neurosurg Psychiatry77, 714–718.
30.
CiafoneJ, LittleB, ThomasAJ, GallagherP (2020) The neuropsychological profile of mild cognitive impairment in Lewy body dementias. J Int Neuropsychol Soc26, 210–225.
31.
HessenE, StavAL, AuningE, SelnesP, BlomsøL, HolmeideCE, JohansenKK, EliassenCF, ReinvangI, FladbyT, AarslandD (2016) Neuropsychological profiles in mild cognitive impairment due to Alzheimer’s and Parkinson’s diseases. J Parkinsons Dis6, 413–421.
32.
ArnaldiD, NobiliF (2018) The clinical relevance of cognitive impairment in REM sleep behavior disorder. Neurology90, 909–910.
33.
Massicotte-MarquezJ, DecaryA, GagnonJF, VendetteM, MathieuA, PostumaRB, CarrierJ, MontplaisirJ (2008) Executive dysfunction and memory impairment in idiopathic REM sleep behavior disorder. Neurology70, 1250–1257.
34.
RahayelS, PostumaRB, MontplaisirJ, Genier MarchandD, EscudierF, GaubertM, BourgouinPA, CarrierJ, MonchiO, JoubertS, BlancF, GagnonJF (2018) Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder. Neurology90, E1759–E1770.
35.
HeinzelS, BergD, GasserT, ChenH, YaoC, PostumaRB (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord34, 1464–1470.
36.
BoccardiM, DodichA, AlbaneseE, Gayet-AgeronA, FestariC, AshtonNJ, BischofGN, ChiotisK, LeuzyA, WoltersEE, WalterMA, RabinoviciGD, CarrilloM, DrzezgaA, HanssonO, NordbergA, OssenkoppeleR, VillemagneVL, WinbladB, FrisoniGB, GaribottoV (2021) The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: Methodological update. Eur J Nucl Med Mol Imaging48, 2070–2085.
37.
ArbizuJ, FestariC, AltomareD, WalkerZ, BouwmanF, RivoltaJ, OriniS, BarthelH, AgostaF, DrzezgaA, NestorP, BoccardiM (2018) Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging45, 1497–1508.
ShimadaH, HiranoS, SinotohH, OtaT, TanakaN, SatoK, YamadaM, FukushiK, IrieT, ZhangM, HiguchiM, KuwabaraS, SuharaT (2015) Dementia with Lewy bodies can be well-differentiated from Alzheimer’s disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. Int J Geriatr Psychiatry30, 1105–1113.
40.
GjerumL, FrederiksenKS, HenriksenOM, LawI, BruunM, SimonsenAH, MecocciP, BaroniM, DottoriniME, KoikkalainenJ, LötjönenJ, HasselbalchSG (2020) Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. Neuroimage Clin27, 102267.
41.
Borght VanderT, MinoshimaS, GiordaniB, FosterNL, FreyKA, BerentS, AlbinRL, KoeppeRA, KuhlDE (1997) Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med38, 797–802.
YoonEJ, LeeJY, KimH, YooD, ShinJH, NamH, JeonB, KimYK (2022) Brain metabolism related to mild cognitive impairment and phenoconversion in patients with isolated REM sleep behavior disorder. Neurology98, E2413–E2424.
47.
BlazhenetsG, MaY, SörensenA, RückerG, SchillerF, EidelbergD, FringsL, MeyerPT (2019) Principal components analysis of brain metabolism predicts development of Alzheimer dementia. J Nucl Med60, 837–843.
48.
NobiliF, SalmasoD, MorbelliS, GirtlerN, PiccardoA, BrugnoloA, DessiB, LarssonSA, RodriguezG, PaganiM (2008) Principal component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol Imaging35, 2191–2202.
49.
PaganiM, NobiliF, MorbelliS, ArnaldiD, GiulianiA, ÖbergJ, GirtlerN, BrugnoloA, PiccoA, BaucknehtM, PivaR, ChincariniA, SambucetiG, JonssonC, De CarliF (2017) Early identification of MCI converting to AD: A FDG PET study. Eur J Nucl Med Mol Imaging44, 2042–2052.
50.
MorbelliS, BaucknehtM, ArnaldiD, PiccoA, PardiniM, BrugnoloA, BuschiazzoA, PaganiM, GirtlerN, NieriA, ChincariniA, De CarliF, SambucetiG, NobiliF (2017) 18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging44, 2073–2083.
51.
WalkerL, McAleeseKE, ThomasAJ, JohnsonM, Martin-RuizC, ParkerC, CollobySJ, JellingerK, AttemsJ (2015) Neuropathologically mixed Alzheimer’s and Lewy body disease: Burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol129, 729–748.
52.
NobiliF, NaseriM, De CarliF, AsenbaumS, BooijJ, DarcourtJ, EllP, KapucuÖ, KempP, VarerC, MorbelliS, PaganiM, SabriO, TatschK, Tossici-BoltL, SeraT, Borght VanderT, Van LaereK, VarroneA (2013) Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: Results from the ENC-DAT database. Eur J Nucl Med Mol Imaging40, 565–573.
